Noveome Biotherapeutics Raises $51M to Propel Breakthrough Regenerative Therapies in Pittsburgh

Noveome Biotherapeutics, Inc. is excited to announce a major milestone in its journey toward transforming regenerative medicine—a successful funding round that raised $51,000,000. As a clinical stage biopharmaceutical company at the forefront of breakthrough therapies, Noveome is uniquely positioned to lead the charge in the regenerative repair of inflamed or damaged tissues. Originally founded as Stemnion, Inc., this innovative company is deeply rooted in Pittsburgh’s vibrant Southside Works area, where it plays a critical role in driving Allegheny County toward becoming a global leader in biotherapeutic research and development. The fresh infusion of capital will empower Noveome to accelerate its pioneering programs, expand its innovative platform technology, and further its collaborations with major research centers. Unlike traditional drugs that target specific indications with single molecules, Noveome’s products are comprised of a complex mixture of biomolecules, offering the potential to treat a wide range of conditions and injuries. This funding will support the company’s ambitious research and clinical development efforts, enabling it to push the boundaries of what is possible in regenerative medicine. In addition, the investment reinforces the company’s commitment to not only advancing its proprietary biotherapeutic solutions but also to fostering the growth of a regional ecosystem that nurtures scientific innovation and economic development. With this significant financial backing, Noveome Biotherapeutics is poised to deliver transformative therapies that could redefine patient care, while also bolstering the stature of Allegheny County as a thriving hub for cutting-edge biopharmaceutical research.